Department of Physical Medicine and Rehabilitation, University of Santo Tomas Hospital, Manila, Philippines.
Arch Phys Med Rehabil. 2010 Aug;91(8):1291-305. doi: 10.1016/j.apmr.2010.02.008.
To evaluate evidence on the effectiveness of topical nitroglycerin (NTG) in treating tendinopathies.
Systematic searches were conducted on ScienceDirect, Scirus, Highwire Press Stanford University, PubMed Central, Directory of Open Access Journals, Free Medical Journals, Free Full Text, Bioline International, Findarticles, BioMed Central, IndMed, OpenMD, QMed, Geneva Foundation for Medical Education and Research, Scientific Electronic Library Online, eMedicine/Medscape/Medline, Biomedical E-journals, Current Contents Connect, Journal of Medical Internet Research, Cochrane, Turning Research Into Practice, Ovid, and EBSCO databases. There were no restrictions regarding the language of publication.
All clinical controlled trials or randomized controlled trials (RCTs) evaluating the effects of NTG for patients with acute, subacute, or chronic tendinopathies, whether the said intervention was placebo-controlled or controlled against a comparator intervention, were considered for inclusion.
A reviewer extracted data from included studies using a data extraction form by the Joanna Briggs Institute.
Methodologic quality of studies was assessed by 2 independent reviewers through a critical appraisal form by the Alberta Heritage Foundation. Qualitative analyses of data were done using a rating system devised by Van Tulder and colleagues. Where possible, meta-analyses of data were performed. Seven clinically relevant and high-quality RCTs involving 446 subjects were identified and included in this review. Meta-analysis showed that NTG has a positive effect in pain reduction during activities of daily living in chronic tendinopathies, with an odds ratio of 4.44 (95% confidence interval [CI], 2.34-8.40), and in both acute and chronic phases combined, with an odds ratio of 4.86 (95% CI, 2.62-9.02). There is also qualitative, strong (Level 1) evidence that NTG is effective in enhancing tendon forces in the chronic phase. There is limited and/or conflicting evidence (Level 3) for other outcomes in the chronic phase and all outcomes in the acute phase. There is a significant between-group difference between NTG and control in the incidence of headache, with an odds ratio of 1.73 (95% CI, 1.01-2.97). No significant difference was observed in the occurrence of contact dermatitis, with an odds ratio of 2.12 (95% CI, .89-5.02).
In chronic tendinopathies, there is strong evidence for NTG in relieving pain during activities of daily living, and increasing tendon strength. Further studies are needed to explore the role of this promising intervention in all phases of tendinopathies.
评估局部硝酸甘油(NTG)治疗肌腱病的疗效证据。
在 ScienceDirect、Scirus、Highwire Press Stanford University、PubMed Central、开放获取期刊目录、免费医学期刊、免费全文、Bioline International、Findarticles、生物医学中心、IndMed、OpenMD、QMed、日内瓦医学教育和研究基金会、科学电子图书馆在线、eMedicine/Medscape/Medline、生物医学电子期刊、当前内容连接、医学互联网研究杂志、Cochrane、将研究转化为实践、Ovid 和 EBSCO 数据库中进行了系统搜索。出版语言没有限制。
所有评估 NTG 对急性、亚急性或慢性肌腱病患者影响的临床对照试验或随机对照试验(RCT),无论该干预措施是否为安慰剂对照或与对照干预措施对照,均被认为符合纳入标准。
一名评审员使用 Joanna Briggs 研究所的数据提取表从纳入的研究中提取数据。
通过 Alberta Heritage 基金会的批判性评价表,由 2 名独立评审员评估研究的方法学质量。使用 Van Tulder 及其同事设计的评分系统对数据进行定性分析。在可能的情况下,对数据进行了荟萃分析。本综述共纳入了 7 项具有临床意义和高质量的 RCT,涉及 446 名受试者。荟萃分析显示,NTG 对慢性肌腱病患者日常活动时的疼痛减轻有积极影响,比值比为 4.44(95%置信区间[CI],2.34-8.40),在急性和慢性阶段均合并,比值比为 4.86(95%CI,2.62-9.02)。还有强有力的(一级)证据表明,NTG 可有效增强慢性阶段的肌腱力量。慢性阶段的其他结局和急性阶段的所有结局均有有限的和/或相互矛盾的证据(三级)。NTG 与对照组相比,头痛的发生率存在显著的组间差异,比值比为 1.73(95%CI,1.01-2.97)。接触性皮炎的发生率无显著差异,比值比为 2.12(95%CI,.89-5.02)。
在慢性肌腱病中,有强有力的证据表明 NTG 可缓解日常活动时的疼痛,并增强肌腱强度。需要进一步研究来探索这种有前途的干预措施在肌腱病所有阶段的作用。